Video
Dr. Abi-Jaoudeh Discusses Potential of Immunotherapy in Advanced HCC
Author(s):
Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.
Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma (HCC).
Immunotherapy, and the combination of immunotherapy with locoregional therapy, could be effective in the field of advanced HCC, says Abi-Jaoudeh.
Currently, sorafenib (Nexavar) is the only FDA-approved frontline treatment for HCC. Abi-Jaoudeh says that leaves a huge space for combinations of immunotherapy and locoregional therapy to flourish.
<<<
